Home > Insider Trading > Filing (0001209191-23-028886)

Filing Details

Accession Number:: 0001209191-23-028886
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-05-11 21:16:01
Reporting Period:: 2023-05-09

Accepted Time:: 2023-05-11 21:16:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1962918	Acelyrin Inc.	SLRN	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1541946	E Sean Harper	C/O Westlake Biopartners, Llc 3075 Townsgate Rd., Suite 140 Westlake Village CA 91361	No	No	Yes	No
1811947	Westlake Biopartners Fund Ii, L.p.	C/O Westlake Biopartners, Llc 3075 Townsgate Rd., Suite 140 Westlake Village CA 91361	No	No	Yes	No
1811948	Westlake Biopartners Gp Ii, Llc	C/O Westlake Biopartners, Llc 3075 Townsgate Rd., Suite 140 Westlake Village CA 91361	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-05-09	8,540,729	$0.00	8,540,729	No	4	C	Direct
Common Stock	Acquisiton	2023-05-09	1,250,000	$18.00	9,790,729	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Redeemable Convertible Preferred Stock	Disposition	2023-05-09	4,056,795	$0.00	4,056,795	$0.00
Common Stock	Series B Redeemable Convertible Preferred Stock	Disposition	2023-05-09	2,445,786	$0.00	2,445,786	$0.00
Common Stock	Series C Redeemable Convertible Preferred Stock	Disposition	2023-05-09	2,038,148	$0.00	2,038,148	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

Represents shares of Common Stock received upon conversion of shares of the reported series of preferred stock on a one-for-one basis without payment of further consideration.
Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. Beth C. Seidenberg and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any.
This report on Form 4 is jointly filed by Westlake Fund II, Westlake GP II and Sean E. Harper. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of such person's or entity's pecuniary interest therein, if any. Westlake Fund II has designated a representative, Beth C. Seidenberg, a Managing Director of Westlake GP II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purpose.
Represents shares of Common Stock purchased in the Issuer's initial public offering of Common Stock (the "IPO").
Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock.
Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.